iiinova — where your digital self keeps evolving

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 13/03/2025

Some contrast to my usual oncology research work - but with a good focus on my #urology background. Talked to @gqmagazine.bsky.social Germany and GoSping.de about #STI #SexuallyTransmittedDiseases and how important #awareness and #treatment is. Great interview! 👉 www.gq-magazin.de/artikel/6-my...

161

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/02/2025

Updated analysis with additional FU of EV 302 EV+P in 1st line advanced #BladderCancer ✅ PFS & OS benefit in all groups ✅ Benefit in cisplatin eligible/ineligible ✅ Safety consistent with prior analysis ✅ mDOR close to 2 years #ascoGU25 @oncodaily.bsky.social

051

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 03/02/2025

Great weekend with a 12 1/3 hrs indoor cycling race 🚴‍♂️🚴‍♀️🚴🚴 Great start into the 2025 season and after recovering from 2024 pelvic fracture

130

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 12/01/2025

Rethinking #ProstateBiopsy protocols: A systematic review (23 studies, 12,324 pts) shows that #AntibioticProhylaxis can safely be omitted in transperineal bx 💉w/o elevating infectious risks 🧫 #ProstateCancer #Urology #AntibioticStewardship @lucacindolo.bsky.social 👉 www.nature.com/articles/s41...

1105

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 11/01/2025

#CREST trial with positive results for #PD-1 in HR #NMIBC! ✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC. ✅The study met its primary endpoint with significant improvement of EFS pfizer.com/news/press-rel… @oncodaily.bsky.social

pfizer.com

153

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Juan Luis Vásquez @jlvasquez82.bsky.social · 10/01/2025

Understanding emotions to enhance leadership 💡❤️‍🔥 @brookmans76.bsky.social led a powerful session on Emotional Intelligence — exploring how self-awareness, empathy, and human connection 🤝 can shape better leaders in healthcare 🌟. #EAUTalentIncubator

042

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Juan Luis Vásquez @jlvasquez82.bsky.social · 09/01/2025

Moving from the dance floor 🕺💃 to the balcony 🏛️” - Great leadership requires both action & reflection. Insightful session by @brookmans76.bsky.social at #EAUTalentIncubator on finding balance in leadership! 👏✨ @uroweb.bsky.social #LeadershipDevelopment

012

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/01/2025

New meta-analysis shows #PDE5 inhibitors, like tadalafil & sildenafil, may modestly reduce HbA1c levels in diabetes, with long-acting inhibitors having a greater impact. Promising dual benefit for managing diabetes & #erectiledysfunction. #Diabetes #PDE5 #HbA1c

198

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Yüksel Ürün @yukselurun.bsky.social · 30/12/2024

Immunotherapy shows sex bias—men respond better; women face more severe AEs. Understanding sex hormones, chromosomes, and epigenetics in immunity could lead to tailored immuno-oncology strategies. #Cancer #Immunotherapy #Oncology @oncoalert.bsky.social rdcu.be/d49Mq

0259

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 23/12/2024

Exercise improves quality of life for #ProstateCancer patients. Our latest systematic review shows combined resistance and aerobic training reduces fatigue, enhances mental and sexual health, and boosts fitness. Resistance training also improves body composition #ProstateCancer #PhysicalExercise

1121

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 21/12/2024

Feels good to realize I am back on @gozwift.bsky.social @zwiftrides.bsky.social to get up to 4 jerseys in one training. Rehab is now definitely over after my pelvic fracture 3 months ago #Roadbike #Cycling Back to real training and rides!

2171

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Yüksel Ürün @yukselurun.bsky.social · 19/12/2024

Genomic sequencing identified hereditary cancer risks in 9% of patients after uninformative gene panels. However, most findings lacked evidence-based guidelines. #Genomics #Cancer #Oncology @oncoalert.bsky.social @viveksubbiah.bsky.social @realbowtiedoc.bsky.social doi.org/10.1200/PO-2...

0169

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 13/12/2024

It is such bad news - and an incredible loss. Felix Feng has been such a wonderful research partner. I will miss him and the great collaboration we had.

060

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 08/12/2024

#Nectin4 in GU vs other malignancies ✅ Nectin4 is more prevalent in GU cancers than others ✅ still more data needed on the prognostic and predictive value 👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer

071

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Scott Hamilton @sdhamiltonvic.bsky.social · 07/12/2024

Choose 20 books that have stayed with you or influenced you. One book per day for 20 days, in no particular order. No explanations, no reviews, just covers. #booksky 📚💙 #bookchallenge #20daybookchallenge 11/20

1121

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 06/12/2024

Impressive results: Ph 2 trial: BCG + gemcitabine in BCG-exposed #NMIBC (HG Ta/T1/CIS) ✅ 6 & 12 mo CR: 94% & 81% ✅ 6, 12 & 18 mo HG-RFS: 97%, 85%, 76% ✅ 2 Gr AEs (UTI, pneumonitis). No Gr 4,5 AEs Phase 3 trial vs BCG will follow #SUO24 #BladderCancer @oncodaily.bsky.social

095

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Matt Cooperberg @dr-coops.bsky.social · 05/12/2024

Great updates from Patrick Hensley and Mark Tyson on the huge and growing array of options for non-muscle-invasive #bladdercancer #SUO24

091

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

The OncoAlert Network 🚨 @oncoalert.bsky.social · 02/12/2024

Frailty in older adults w/ #ProstateCancer is a significant challenge, as it can affect both the prognosis and treatment decisions. Frailty results from aging-related declines in physiological reserves and exacerbated by both ADT & the cancer itself, leading to sarcopenia & reduced bone density

061

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 30/11/2024

He was and is an icon and legend #VirgilAbloh Thank you @oncodaily.bsky.social for remembering him I can also recommend reading his Abloh-isms

020

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Yüksel Ürün @yukselurun.bsky.social · 27/11/2024

Life expectancy gaps in the US 🇺🇸 have widened—now over 20 years between groups. Geography, race, & income remain key drivers. 🌍 Globally, disparities may be even worse. Inequities demand urgent action. #HealthDisparities #Longevity #EquityInHealth @oncoalert.bsky.social @ptarantinomd.bsky.social

0114

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 27/11/2024

AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment Some questions remain to be answered related to: ▶️ Heterogeneity of disease ▶️ Interreader variability of pathology assessment ▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social

095

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 26/11/2024

Interesting paper showing that #antibiotics may reduce cancer risk by depleting gut microbiota metabolizing nitrosamines #BladderCancer #Microbiome But (not discussed in the paper): 🚩AB can also disrupt beneficial microbial functions 🚩Increase cancer risk 🚩Negatively impact outcomes of IO therapy

050

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Gil Morgan MD @weoncologists.bsky.social · 26/11/2024

Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨

0167

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Yüksel Ürün @yukselurun.bsky.social · 24/11/2024

Early detection of RCC faces unique challenges. As one of the lowest-shedding tumors with few recurrent mutations, genomic approaches remain limited. Novel cfDNA methylation profiling shows promise for non-invasive diagnosis, offering potential breakthroughs in precision medicine. #Oncology

081

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Juan Luis Vásquez @jlvasquez82.bsky.social · 23/11/2024

Another successful module! Thank you so much for your contribution and constant support! ❤️

011

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 23/11/2024

EAU Talent Incubator Module 4 in Berlin was a great one again! Active participants, great topics #Policy #Innovation important for academic and non-academic urologists, and perfect network opportunity @uroweb.bsky.social @jlvasquez82.bsky.social

2112

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

GU Cast | Declan Murphy & Renu Eapen @gu-cast.bsky.social · 23/11/2024

Declan Murphy discusses fast track queues at the Pearly Gates and doublet vs triplet therpy for mHSPC! Teaser for current GU Cast PROSPECT Part 2 #urology #podcast #prostatecancer

173

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Urology On Air @urology-on-air.bsky.social · 19/11/2024

More information about Urology On Air coming soon... www.youtube.com/watch?v=XlVT...

youtube.com

Urology on Air coming soon

YouTube video by hub.

012

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Yüksel Ürün @yukselurun.bsky.social · 20/11/2024

RADICALS-HD: Adding ADT to postop RT in prostate cancer shows no MFS improvement. Long-term outcomes remain favorable, even without ADT. High-risk cases need focus! @oncoalert.bsky.social DOI: 10.1016/j.eururo.2024.07.026

2154

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024

Just out: Our multicenter study comparing Uromonitor® DNA assay to #UrineCytology for #BladderCancer ✅ TERT & FGFR-3 mutations strongly predict UCB ❌ 93.3% specificity, but 49.3% sensitivity only ❌ KRAS mutations lacked predictive value. 🤔 The quest for optimal non-invasive #biomarker continues

030

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024

Please count me in. Besides pelvic floor was never my primary focus as urologist/oncologist, I developed a few years ago the first digital healthcare app for pelvic floor training for men after #ProstateCancer treatment 👉 Pelvintense. www.pelvintense.de (Android). Study results to be presented soon!

pelvintense.de

Profitieren Sie von einem effektiven Trainingsprogramm, das Sie einfach in Ihren Alltag integrieren können.

321

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 20/11/2024

Just in @bjuijournal.bsky.social: Our #TITAN post hoc analysis: Patients with ultralow 0.2 #PSA derived greatest beneﬁt. Less pronounced addtl. benefit for .02 #mHSPC #ProstateCancer 👉https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1111/bju.16449 @oncoalert.bsky.social @uroweb.bsky.social

0148

Reposted by Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 19/11/2024

Sunrise 2 was recently stopped based on the IDMC recommendation as TAR-200 + Cetrelimab didn't show superiority over chemoradiation. But SR4 still ongoing. And T0 rates (also of other treatments) raise the hope for potential #bladdersparing approaches! #TAR200 #MIBC

141

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 19/11/2024

Great idea to look for most important recent #BladderCancer papers. There is a lot going in both the advanced and also in the localized disease setting right now #NMIBC #MIBC indicating a potential also for bladder-sparing approaches

040

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 18/11/2024

Coming back from Boston last Friday still with crutches due to my #Roadbike accident + pelvic fracture, I decided to get rid of them now and start getting my fitness back on @gozwift.bsky.social @gozwift.bsky.social 7 weeks of muscle and power loss are enough💪🚴‍♀️🚴‍♀️🚴‍♀️

280